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Opinion statement
Specialists’ views of fibromyalgia (FM) are typically colored by their experiences of the
selected, complex cases that they are regularly called to evaluate. At a population
level, it is crucial to recognize that education which promotes patient empowerment
and non-pharmacological interventions which support self-management are very effec-
tive. The temptation, for both physician and patient, to first reach for pharmacological
interventions should be resisted until such holistic approaches are explored. In
particular, a strong evidence base supports graded exercise and cognitive behavioral
therapies, but such treatments must be intelligently Bprescribed.^ As reflected by the
recent ACR criteria, FM is a highly heterogeneous disorder and is not simply a disorder
of pain. For some patients, co-occurring symptoms, such as fatigue, can be equally as
impactful and so management strategies should be sufficiently versatile to target
those dimensions which are considered priorities at the level of the individual patient.
In those patients who do require pharmacological support, patients should not be led
to expect significant gains in isolation. The importance of self-management requires
emphasis at each and every tier of management. It is true that advances in our
understanding of neurobiology have greatly informed the selection of adjunctive drug
classes which may provide benefit (as well as those which do not—as is the case of
opioids). However, further unpicking of pathogenesis is still required if the FM
landscape is to move further towards drug-led management.
Introduction
Proposed genealogies of the syndrome now known
as fibromyalgia (FM) stretch back as far as the late
sixteenth century [1]. Key historical moments in its
emergence as a distinct entity include the 1904 debut
of fibrositis [2] and Hench’s introduction of the term
Bfibromyalgia^ in 1976 [3]. The American College of
Rheumatology (ACR) first published classification
criteria in 1990 [4••], characterizing FM as chronic
widespread pain (pain in the axial skeleton and on
both sides of the body, above and below the waist,
for at least 3 months), plus 11 out of a possible 18
tender points on clinical examination. The ACR dis-
seminated revised criteria in 2010, the update
shifting the emphasis from classification to diagnosis
[5••]. The tender point requirement was replaced by
recognition of the importance of patient-reported
symptoms, including somatic, cognitive, and mood
disorders. The revised criteria allowed FM to be mea-
sured on a continuous scale that incorporated the
widespread-ness of pain and the severity of concur-
rent symptoms. A modified version of the 2010
criteria was published a year later (2011), and these
were used to develop a questionnaire for use in
clinical and epidemiological studies of the syndrome
[6••]. The mean worldwide prevalence of FM has
been estimated to be 2.7 %, with a higher occurrence
in women and those of middle or older age and
lower socioeconomic status [7]. US prevalence has
been estimated as 2.2 % using the 1990 ACR criteria
[8] and 6.4 % using the 2010 ACR criteria [9].
Advances in the understanding of the underlying
pathophysiology, including recognition of the role
of central pain sensitization, have informed FM man-
agement. Findings from studies investigating pharma-
cological, non-pharmacological and complementary,
and alternative therapies have been summarized in
clinical practice guidelines (CPG). These include The
European League Against Rheumatism’s (EULAR) ap-
praisal of the literature, published in 2008 [10•],
which is currently being updated. This document
was one of six CPGs that contributed to a systematic
review of guidelines published up to 2014 [11••]
which forms the basis of the evidence provided
below.
Treatment
Given the heterogeneous symptomology of FM, it may be unsurprising
that multimodal, multidisciplinary management has been widely advo-
cated. This approach was supported by the highest level of evidence
grading (A1: several randomized clinical trials with p G 0.01 with meta-
analysis) and the strongest possible recommendation (A: benefit signif-
icantly outweighs adverse effects and should be applied to all eligible
patients) in a recent systematic review of CPGs [11••] that included
German and Canadian recommendations [12•, 13•]. Emphasis is placed
on patient education and self-management, with the integration of non-
pharmacological and then pharmacological treatments as indicated by
concomitant, uncontrolled symptoms, including severe pain, mood dis-
orders, sleep problems, and fatigue. Two non-pharmacological treat-
ments have received the highest ratings for level of evidence: exercise
and cognitive behavioral therapy (CBT) [11••]. Accordingly, non-
pharmacological treatment options are considered first here, followed by
pharmacological treatments, and then complementary and alternative
therapies. The development and effectiveness of management plans that
select from this pool of options would sensibly be stratified according to
the individual patient’s priorities. The revised Fibromyalgia Impact
Questionnaire (FIQR) is one useful tool which may aid the multi-
disciplinary team in the design of bespoke multimodal therapy packages.
This reliable and valid multidimensional assessment can also be
employed to monitor function, symptoms, and the overall impact of FM
over time [14].
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Non-pharmacological treatment
Education
Patient education is the keystone of multimodal FM management. The
educational component should develop the individual’s understanding of
the pathophysiology of FM, especially the recent advances in neurobiology,
in the context of a biopsychosocial model of health and illness. Education
regarding the importance of self-management that includes information on
exercise, sleep habits, and the setting of realistic expectations, should be
supported [13•, 15•] and can rarely be achieved during a single session.
The effectiveness of patient education has been demonstrated in a number
of trials when it is provided as part of a multimodal management package.
The provision of an online repository of information and resources which
empower patients may be of particular benefit in supporting education,
self-management, and improving symptom control and quality of life
[11••, 16•].
Exercise
Exercise has been identified as effective in managing a range of FM
symptoms, including pain, reduced activity, and poor quality of life. A
Cochrane review collated the evidence for 47 different types of exercise
therapies and determined aerobic exercise to be associated with reductions
in pain, number of tender points, and functional limitation [17••]. A later
review found similar benefits in response to strengthening exercises [18],
and more recent research has supported the effectiveness of aquatic exercise
[19]. Given a lack of evidence to support any one specific exercise modality
over others, cost, patient preference, and the likelihood of long-term ad-
herence are factors to discuss and agree upon during the development of a
management plan. Research that has objectively measured physical activity
levels has determined that individuals with chronic pain are less active than
those without chronic pain [20]. This relationship may, in part, be ex-
plained by beliefs held by individuals with chronic pain regarding move-
ment and symptom exacerbation [21]. Unhelpful beliefs may be given
traction if exercise is not introduced in a graded manner, with negative
experiences after unpaced exercise deterring future participation. Indeed, the
word Bexercise^ itself may cause trepidation in some individuals with
chronic pain, so focusing on increasing activity in general may be a
preferable starting point. Guidelines have proposed sessions of moderate to
mild intensity activity for a 30-min duration at least two times a week
[11••, 12•, 13•]. Garcia et al. found exercise to be included in all CPGs
identified up to 2014 and awarded it the highest ratings for both level of
evidence and strength of recommendation [11••], highlighting the central
role it plays in FM symptom management.
Cognitive behavioral therapy
Cognitive behavioral therapy (CBT) can be used to target negative thoughts
about pain and its exacerbation on activity and can support behavior change
through improvements in symptom management self-efficacy [12•, 13•].
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Along with exercise, CBT received the highest rating for level of evidence in a
synthesis of CPGs [11••]. A 2013 meta-analysis of 23 randomized controlled
trials investigated the impact of CBT on pain, function, and mood in individ-
uals with FM [22••]. Positive, yet modest, effects were observed both at the end
of treatment and in the longer term for all outcomes. Evidence suggests that CBT
is effective regardless of mode of delivery (one-to-one, group therapy, or inter-
net-based). The choice of medium may be informed by availability, cost-effec-
tiveness, location and, importantly, the patient’s preference and existing com-
mitments (for example, occupational or homecare duties and geographical
location) [23]. Consideration of, and response to, these factors may support
adherence to a full course of therapy, with consequent associated benefits. An
important point to note is that acceptance of CBT may be reduced if it is
perceived as a purely psychological intervention [15•]. Instead, CBT as one facet
of a multimodal management plan should be fully explained as part of the
educational component. It is also too simplistic to consider CBT as a single
therapeutic entity which may be Btaken off the shelf^ and applied uniformly.
Existing programs are not necessarily underpinned by the same behavioral
models, and perhaps the most optimal strategy is to enable patients to inform
the selection of specific themed CBT modules which align best with their
individual needs. As an example, some patients may well benefit more from
targeting of their fatigue rather than their pain. Such program versatility has
been successfully tested and resulted in significant benefits out to 2 years [24].
Finally, CBT programs may be delivered at varying intensities. So called Blow
grade^ CBT has been successfully delivered in many disorders by trained health
professionals who do not have a background in psychology [25]. Such an
approach is clearly attractive in many health care systems where access to
psychologists is limited by costs and/or limited availability.
Pharmacologic treatment
The pharmacological treatment of FM is largely an Boff-label^, testament
to the fact that, in the USA, only three drugs are currently Food and
Drug Administration (FDA)-approved (pregabalin, duloxetine, and
milnacipran). In comparison, two are approved by Health Canada
(pregabalin and duloxetine) and none are approved by the European
Medicines Agency [26•]. The efficacy of a broad range of pharmacolog-
ical treatments has been investigated in randomized controlled trials. In
general, pharmacological treatment, restricted to the shortest duration
possible, should be reserved for cases of severe and uncontrolled
symptoms, including pain, sleep, and mood disorders, when non-
pharmacological options have been exhausted.
Anti-depressants
Classes of anti-depressant frequently used to treat individuals with FM
symptoms include tricyclic anti-depressants, Serotonin Norepinephrine
Reuptake Inhibitors (SNRIs), and Selective Serotonin Reuptake Inhibitors
(SSRIs). Pain reductions resulting from their use are attributed to mod-
ulating effects on serotonin and norepinephrine in descending inhibitory
pain pathways [27].
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Tricyclic anti-depressants
Amitriptyline is the most studied anti-depressant in the treatment of FM-
related symptoms. Clinical trials have demonstrated reductions in pain,
sleep problems, and fatigue, although the methodological quality of stud-
ies has been questioned [28]. Improvements have been identified 6 to
8 weeks after commencement at low doses (25 mg/day), but no benefit
identified with either an increased dose (50 mg/day) or after a longer
duration (12 weeks) when compared to placebo [29]. The Garcia et al.
summary of published CPGs rated the level of evidence for amitriptyline as
A1, recommending its prescription, at a dose of 10–50 mg/day, for those
with severe, uncontrolled pain and sleep problems [11••, 12•, 30•].
Common side effects include drowsiness, dry mouth, and weight gain, and
many patients find that such problems outweigh any gains in symptom
relief.
Serotonin norepinephrine reuptake inhibitors
Duloxetine A systematic review of the efficacy of duloxetine reported a reduction of
greater than 30 % for pain effective doses being between 60–120 mg/
day, with no difference detected between doses [31•] and lower doses
(20–30 mg/day) not demonstrating significant effects. Modest, positive
effects on sleep and function have also been reported [32•]. The Span-
ish and German guidelines, published in 2011 and 2012, respectively
[12•, 30•], identified duloxetine as the preferred SNRI, prescribed at a
dose of 60 mg/day, for those with comorbid anxiety or depression in
cases where amitriptyline is contraindicated or ineffective (level of evi-
dence A1) [11••]. Possible side effects of duloxetine include nausea,
palpitations, headache, fatigue, tachycardia, and hypertension [15•].
Milnacipran A Cochrane review conducted by Hauser et al. that investigated the
effects of SNRIs on FM symptoms identified five studies that compared
milnacipran with placebo [32•]. Its use was associated with a small
incremental benefit for pain reduction and slight improvements in
fatigue and quality of life but no improvements detected for sleep
problems. An effective dose of 100–200 mg/day has been proposed with
potential side effects including nausea, palpitations, headache, fatigue,
tachycardia, and hypertension [15•]. It has been suggested that, as
milnacipran is slightly more noradrenergic than duloxetine, it may be
more suitable for individuals presenting with fatigue and memory
problems [15•]. However, as it may also be more likely to precipitate
hypertension, careful balancing of benefits and risks on a case-by-case
basis is required.
Selective serotonin reuptake inhibitors
SSRIs used to treat FM symptoms include fluoxetine, paroxetine, and
sertraline. In a meta-analysis of the effects of fluoxetine, a moderate effect
on pain and modest effects on sleep and fatigue were detected [33]. Side
effects of SSRIs include nausea, sexual dysfunction, and weight gain [15•].
Fluoxetine or paroxetine (20–40mg/day) have been identified by two 2012
guidelines as worthy of consideration for those with comorbid anxiety of
depression [12•, 13•].
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Anticonvulsants
The analgesic effect of anticonvulsants is thought to occur through a reduction
in the release of neurotransmitters involved in pain processing, e.g., glutamate
and substance P [34]. This class of drugs was developed, and subsequently
licensed, as antiepileptics but they are now commonly used in themanagement
of chronic pain [26•].
Pregabalin Pregabalin is FDA-approved for FM symptom management. A Cochrane review
from 2013 reported a 30 % reduction in pain but a modest effect on fatigue and
sleep and no impact on function [35•]. Standard dosages range from 50–
450mg/day [11••, 12•, 30•], to up to 600mg/day, in divided doses. Side effects
include sedation, weight gain, and dizziness [15•]. Garcia et al. recommend its
consideration if amitriptyline is contraindicated or ineffective (level of evidence:
A2—several randomized clinical trials have provided evidence p G 0.01 without
meta-analysis strength of recommendation: B—can be recommended) [11••].
Gabapentin The use of gabapentin for FM symptommanagement is relatively understudied. A
Cochrane review that investigated gabapentin in the treatment of neuropathic pain
and FM (date of most recent search January 2011) [36•] included only one study
that investigated its effect on FM symptoms [37]. This study reported an im-
provement in pain (significant 30 % reduction) and function and a modest effect
on sleep problems. A dose range of 800–2400mg/day, in divided doses, has been
suggested. Side effects include sedation, weight gain, and dizziness [15•].
Nonsteroidal anti-inflammatory drugs (NSAIDs)
There is no evidence to support the efficacy of NSAIDs in managing FM-related
pain, with trials consistently demonstrating no benefit over placebo [38].
Indeed, there is evidence to suggest that drugs frequently used to treat peripheral
pain, such as NSAIDs and opioids, are not only ineffective, but may exacerbate
symptoms [15•]. Given the potentially deleterious side effects affecting the
gastrointestinal, renal, and cardiac systems, this class of drugs should only be
prescribed in cases of persistent andmoderate to severe peripheral pain. In such
instances, the lowest effective dose possible should be prescribed for the
shortest duration to minimize any secondary effects [15•].
Opiods
The apparent hyperactivity of the endogenous opioid system in FM perhaps
explains the general inefficacy of opiods [15•]. Tramadol has however been
commonly used, although any benefitmay actually relate to itsmild SNRI effects.
Recommendations regarding tramadol use are inconsistent across CPGs. Its use
has been associated with significant pain reduction (30%) [39], although Garcia
et al. recommend its use only once all other pharmacological options have been
exhausted and in cases of persistent moderate or severe pain [11••]. Tramadol
dosage, with or without acetaminophen, has been suggested at 50–100mg every
6 h. Side effects to be cognizant of include sedation, possible addiction, the
development of tolerance, and opioid-induced hyperalgesia [15•].
Complementary and alternative therapies
In their systematic review of CPGs for the management of FM, Garcia et al.
identified four alternative therapies that were recommended by more than one
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guideline: acupuncture, Qi Gong, Tai Chi, and yoga [11••]. However, given
limited corroboration of findings, further research is required to support the
effectiveness of these therapeutic options, as well as to determine the benefit of
other alternative or complementary approaches. However, as adjuncts to non-
pharmacological and pharmacological interventions, patient preference and
selection of complementary or alternative therapiesmay provide a useful way of
engaging individuals with active symptommanagement, encouraging Bbuy-in^
to self-care, and potentially enhancing self-efficacy [15•]. Furthermore, in cir-
cumstances where all else fails, patient-directed alternative approaches (as long
as they are safe) may most optimally tap into clinically important placebo
responses.
Conclusions
A range of treatment modalities to address complex and heterogeneous FM
symptoms should be explored in collaboration with patients. Understand-
ing the individual’s needs and specific symptoms that are restricting activ-
ities and participation is key to the development of tailored treatment
plans. Education, exercise, and active self-management are highly recom-
mended, providing the core around which pharmacological and non-
pharmacological treatments and complementary and alternative therapy
adjuncts can be supplemented. Importantly, education should acknowledge
the limits of pharmacological treatments in resolving symptoms, and self-
management should be promoted within the context of realistic expectation
setting. Exercise comes most highly recommended followed by CBT. Short
courses of pharmacological treatment are indicated when symptoms are
particularly burdensome. Overall, a personalized approach is indicated,
where, above the staple of education and encouragement of positive exer-
cise, sleep and stress reduction behaviors, and additional psychological
interventions (i.e., CBT) may be of benefit for those with unhelpful coping
strategies and pharmacotherapy may be indicated in cases of severe pain,
sleep disturbance, or mood disorders. Through actively involving patients
in the design of a multimodal management plan that takes into consider-
ation the preferred method and timing of delivery, self-efficacy and a
sustained commitment to behavior change may provide the optimal atmo-
sphere for long-term symptom management.
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